ArticleJNCI cancer spectrum2025
Therapy-Related-Myeloid-Neoplasm-Risk Score: a convenient score for therapy-related myeloid neoplasms risk assessment in adult cancer patients.
Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA prediction model for estimating risk of therapy-related myeloid neoplasms (tMNs), a late effect with a high mortality after chemotherapy and/or radiation, is currently unavailable. Ability to predict risk at initial cancer presentation can be key for early detection and risk mitigation.
methodsUsing SEER-Medicare linked database, 970 390 adults diagnosed with first primary cancer from 2000 to 2011 (with follow-up through 2015) were selected. The sample was divided into training (n = 582 234) and validation cohorts (n = 388 156). Various tMN risk factors were used for the development of tMN prediction model: the Therapy-Related Myeloid Neoplasm Risk Score (TMNRS). TMNRS was created as a simple arithmetic sum of independent predictors of tMN weighted according to the adjusted hazard ratio from the Cox proportional hazards analysis.
resultsIn addition to the known risk factors of chemotherapy and radiation exposure, history of autoimmune disease and granulocyte-colony stimulating factor exposure emerged as consistent predictors of tMN after each of the 5 cancers in the study. Cancer survivors were categorized into distinct risk groups with variable risk of tMN.
conclusionTMNRS provides a simple and convenient office-based mechanism to identify solid cancer patients at variable risks of tMN development. This risk assessment tool provides preliminary insights that may contribute to future research on the management of patients, particularly those receiving adjuvant therapies. Further investigation is required to fully evaluate its clinical utility and potential effects on patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.